DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
ANTI-PSGL-1 ANTIBODY SELK2
2
Unknown
Investigational
Unknown
Unknown
Venous Thromboembolism
Unknown
ANTI-PSGL-1 ANTIBODY SELK2
×
Maximum Phase:
2
First Approval:
None
UNII:
FR57BKG0QJ
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CR 1447
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Androgen Receptor agonist
CR 1447
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GI-6301
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GI-6301
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HANK
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
HANK
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RADIPRODIL
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Spasms, Infantile
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
RADIPRODIL
×
Maximum Phase:
2
First Approval:
None
UNII:
5XGC17ZKUF
Molecule Type:
Small molecule
Molecular Formula:
C21H20FN3O4
Molecular Weight:
397.41
AlogP:
2.68
PSA:
95.41
HBD:
2.0
HBA:
#RotB:
3.0
Source:
DAR-0100A
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DAR-0100A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
A-002
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
A-002
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APIMOSTINEL
2
Protein
Investigational
Unknown
Unknown
Depressive Disorder, Major; Schizophrenia
Glutamate [NMDA] receptor partial agonist
APIMOSTINEL
×
Maximum Phase:
2
First Approval:
None
UNII:
TTT1F11FZB
Molecule Type:
Protein
Molecular Formula:
C25H37N5O6
Molecular Weight:
503.6
AlogP:
-1.36
PSA:
179.29
HBD:
5.0
HBA:
#RotB:
9.0
Source:
AZD8683
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Muscarinic acetylcholine receptor M3 antagonist
AZD8683
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XTL-6865
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
XTL-6865
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGDINETANIB
2
Protein
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma
Vascular endothelial growth factor receptor 2 inhibitor
PEGDINETANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
SSB56T0M0L
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRATOSARTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Solute carrier family 22 member 12 inhibitor
PRATOSARTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
66VLQ6E6DL
Molecule Type:
Small molecule
Molecular Formula:
C25H26N6O
Molecular Weight:
426.52
AlogP:
4.64
PSA:
89.35
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PD-217014
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome; Pain
Unknown
PD-217014
×
Maximum Phase:
2
First Approval:
None
UNII:
K2T93E812G
Molecule Type:
Small molecule
Molecular Formula:
C11H19NO2
Molecular Weight:
197.28
AlogP:
1.31
PSA:
52.32
HBD:
1.0
HBA:
#RotB:
3.0
Source:
SETRUSUMAB
2
Antibody
Investigational
Unknown
Unknown
Hypophosphatasia; Kidney Diseases; Osteogenesis Imperfecta
Sclerostin inhibitor
SETRUSUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
FPW3780T3E
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HEMOGLOBIN GLUTAMER
2
Small molecule
Investigational
Unknown
Unknown
Coronary Disease; Peripheral Vascular Diseases
Unknown
HEMOGLOBIN GLUTAMER
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PILARALISIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lymphoma; Neoplasms; Endometrial Neoplasms
PI3-kinase class I inhibitor
PILARALISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
60ES45KTMK
Molecule Type:
Small molecule
Molecular Formula:
C25H25ClN6O4S
Molecular Weight:
541.03
AlogP:
4.51
PSA:
148.33
HBD:
4.0
HBA:
#RotB:
8.0
Source:
ADAGLOXAD SIMOLENIN
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Ovarian Neoplasms; Breast Neoplasms
Globohexaosylceramide vaccine antigen
ADAGLOXAD SIMOLENIN
×
Maximum Phase:
2
First Approval:
None
UNII:
UCG949AA7Z
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L 756423
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
L 756423
×
Maximum Phase:
2
First Approval:
None
UNII:
862SGU1BRL
Molecule Type:
Small molecule
Molecular Formula:
C39H48N4O5
Molecular Weight:
652.84
AlogP:
4.22
PSA:
118.28
HBD:
4.0
HBA:
#RotB:
11.0
Source:
PCS-499
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Renal Insufficiency, Chronic; Necrobiosis Lipoidica
Unknown
PCS-499
×
Maximum Phase:
2
First Approval:
None
UNII:
FLV771E8ZV
Molecule Type:
Small molecule
Molecular Formula:
C13H20N4O3
Molecular Weight:
285.36
AlogP:
-0.02
PSA:
82.05
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TELBERMIN
2
Protein
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Diabetic Foot
Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist
TELBERMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
22G76ZW50X
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SABARUBICIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Testicular Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
SABARUBICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
XS499WOZ93
Molecule Type:
Small molecule
Molecular Formula:
C32H37NO13
Molecular Weight:
643.64
AlogP:
-0.13
PSA:
235.53
HBD:
7.0
HBA:
#RotB:
6.0
Source:
1-OCTANOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
1-OCTANOL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANAVIP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ANAVIP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GC-4711
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Unknown
GC-4711
×
Maximum Phase:
2
First Approval:
None
UNII:
FW5T90VM32
Molecule Type:
Small molecule
Molecular Formula:
C27H45MnN5O4
Molecular Weight:
558.63
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GANAPLACIDE
2
Small molecule
Investigational
Unknown
Unknown
Malaria; Malaria, Falciparum
Unknown
GANAPLACIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
85VMN9JU7A
Molecule Type:
Small molecule
Molecular Formula:
C22H23F2N5O
Molecular Weight:
411.46
AlogP:
3.61
PSA:
76.18
HBD:
2.0
HBA:
#RotB:
4.0
Source:
PIROMELATINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Sleep Initiation and Maintenance Disorders
Melatonin receptor agonist
PIROMELATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
S3UN2146K9
Molecule Type:
Small molecule
Molecular Formula:
C17H16N2O4
Molecular Weight:
312.33
AlogP:
2.1
PSA:
84.33
HBD:
2.0
HBA:
#RotB:
5.0
Source:
PF-04634817
2
Small molecule
Investigational
Unknown
Unknown
Renal Insufficiency; Diabetic Nephropathies
C-C chemokine receptor type 2 antagonist
PF-04634817
×
Maximum Phase:
2
First Approval:
None
UNII:
51M3FB9B9E
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
(+/-)NICOTINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
(+/-)NICOTINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C10H14N2
Molecular Weight:
162.24
AlogP:
1.85
PSA:
16.13
HBD:
0.0
HBA:
#RotB:
1.0
Source:
UR-63325
2
Small molecule
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal
Histamine H4 receptor antagonist
UR-63325
×
Maximum Phase:
2
First Approval:
None
UNII:
B61N8R7TDH
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QLT0074
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
QLT0074
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABT-925
2
Unknown
Investigational
Unknown
Unknown
Schizophrenia
Dopamine D3 receptor antagonist
ABT-925
×
Maximum Phase:
2
First Approval:
None
UNII:
E6CKI5C54O
Molecule Type:
Unknown
Molecular Formula:
C20H27F3N6OS
Molecular Weight:
456.54
AlogP:
3.59
PSA:
78.27
HBD:
1.0
HBA:
#RotB:
6.0
Source:
JNJ-42165279
2
Small molecule
Investigational
Unknown
Unknown
Child Development Disorders, Pervasive; Phobic Disorders
Anandamide amidohydrolase inhibitor
JNJ-42165279
×
Maximum Phase:
2
First Approval:
None
UNII:
AH2E5UQ11Y
Molecule Type:
Small molecule
Molecular Formula:
C18H17ClF2N4O3
Molecular Weight:
410.81
AlogP:
3.41
PSA:
66.93
HBD:
1.0
HBA:
#RotB:
3.0
Source:
CARRAGEENAN
2
Unknown
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome; Conjunctivitis, Viral; Papillomavirus Infections
Unknown
CARRAGEENAN
×
Maximum Phase:
2
First Approval:
None
UNII:
5C69YCD2YJ
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMI-137
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
EMI-137
×
Maximum Phase:
2
First Approval:
None
UNII:
IT54DZ1478
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IBERDOMIDE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Sarcoidosis; Smoldering Multiple Myeloma; Multiple Myeloma
Unknown
IBERDOMIDE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
79L3645KFI
Molecule Type:
Small molecule
Molecular Formula:
C25H28ClN3O5
Molecular Weight:
485.97
AlogP:
1.86
PSA:
88.18
HBD:
1.0
HBA:
#RotB:
6.0
Source:
1
2
…
143
144
145
146
147
148
149
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA